Abstract
AbstractInfection rate of hepatitis B virus (HBV) in our country remains high. Many patients showed combined HBV infection; the most common blood system disease is non-Hodgkin’s lymphoma (NHL)-combined HBV infection. Drugs used in treating lymphoma may induce different degrees of HBV reactivation. Such condition may lead to hepatic failure or death. Currently, scholars pay increasing attention to reactivation of HBV by rituximab and/or chemotherapy for NHL-combined HBV patients. This study summarizes research advances in this topic, with a view of providing background information for further research.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference27 articles.
1. Research Status of Chemotherapy for B Cell Lymphoma Chinese Journal of;Guan;Oncology,2005
2. Hepatitis B virus infection and B - cell non - Hodgkin s lymphoma in a hepatitis B endemic area : a case - control study;Kin;Jpn J Cancer Res,2002
3. Systematic review : the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy;Loomba;Ann Intern Med,2008
4. A revisit of prophylactic lamivudine for chemotherapy - associated hepatitis B reactivation in non - Hodgkin s lymphoma : a randomized trial;Hsu;Hepatology,2008
5. Therapy and Prevention Effect of Lamivudine on HBV Reactivation in HBsAg Carrier with Immune Default Journal of Chinese Modern;Liang;Medicine,2005